Document is current
Any future updates will be listed below
-
Authors
Gueguen, Cindy
Burke, Sandra L.
Barzel, Benjamin
Eikelis, Nina
Watson, Anna M. D.
Jha, Jay C.
Jackson, Kristy L.
Sata, Yusuke
Lim, Kyungjoon
Lambert, Gavin W.
Jandeleit-Dahm, Karin A. M.
Cooper, Mark E.
Thomas, Merlin C.
Head, Geoffrey A. https://orcid.org/0000-0002-7623-137X
-
Funding
Funding for this research was provided by:
Swinburne Research
Boehringer Ingelheim (IIS-02-058)
National Health and Medical Research Council (GNT1079645)
- License Information
-
More Information
Article History
Received: 21 January 2020
Accepted: 10 March 2020
First Online: 5 May 2020
Authors’ relationships and activities
: GAH, MCT and MEC received research support from Boehringer Ingelheim for this project. MCT and MEC have received honoraria for educational meetings and for advisory boards conducted on behalf of pharmaceutical companies involved in treatment with SGLT2 inhibitors including Boehringer Ingelheim, Astra Zeneca, MSD, Lilly and MundiPharma. All other authors declare that there is no conflict of interest with their contribution to this manuscript. Boehringer Ingelheim was involved in study design and approved the decision to submit the report for publication.
Free to read: This content has been made available to all.
